Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir
Abstract Outcomes of various clinical studies for the coronavirus disease 2019 (COVID-19) treatment indicated that the drug acts via inhibition of multiple pathways (targets) is likely to be more successful and promising. Keeping this hypothesis intact, the present study describes for the first-time...
Guardado en:
Autores principales: | Santosh Kumar Behera, Nazmina Vhora, Darshan Contractor, Amit Shard, Dinesh Kumar, Kiran Kalia, Alok Jain |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/571d18671e3846828d659367d9803e1d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
por: Syed Hani Abidi, et al.
Publicado: (2021) -
Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov K, et al.
Publicado: (2020) -
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
por: Hanjun Zhao, et al.
Publicado: (2021) -
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
por: Sulejmani N, et al.
Publicado: (2018) -
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
por: Li H, et al.
Publicado: (2020)